At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
In Brief
A Phase 2 clinical trial evaluating Canagliflozin 50 mg, Placebo, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 279 participants across 61 sites in 7 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (ie, treatment with a single drug) and have inadequate glycemic (blood sugar) control.
Study Details
Timeline
Interventions
One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
1 placebo capsule taken orally twice daily with a meal for 18 weeks
1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
The patient's stable daily dose of Metformin background therapy should be continued throughout the study.